European Antibody Congress - Agenda Day 2

 

European Antibody Congress 2018, Day 2

08:00 Registration Opens

08:50 Conference doors open

Keynote: Combination therapies

08:55

Chair's opening remarks

Panel discussion
09:00

Keynote panel: Combination therapy strategies

  • Combination therapies – what are the next steps?
  • Toxicity and efficacy
  • Latest research and news
Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals
09:40

Title TBC

10:00

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

10:20 Networking refreshment break

Targeting and specificity

Bispecific discovery

Armed antibody development - Pre-clinical development

CMC and Developability

Chaired by TBC

Chaired by TBC

Chaired by TBC

Chaired by TBC

Armed Antibodies
11:25

Pre-clinical development of HuMax-AXL-ADC

  • Axl as a therapeutic target in human cancers
  • HuMax-AXL-ADC antibody generation and mechanism of action
  • Efficacy data for HuMax-AXL-ADC in preclinical models
 
CMC and Developability
11:25

Cutting edge analytical and multiple attributes methods for mAbs and ADCs

  • 2 to 4D - LC-MS profiling and structure assessment
  • Insights gained from native, Ion Mobility, HILIC and CE mass spectrometry
  • Forced degradation, developability and comparability workflows
 
Protein Engineering
11:45

The importance of antibody isotype and Fc receptor interactions in engineering cancer immunotherapies

  • Immunomodulatory mAb can employ multiple mechanisms in tumours
  • Potential mechanisms depend on mAb isotype and FcγR availability
  • mAb engineering can allow multiple mechanisms to be engaged to therapeutic effect
 
Bispecifics
11:45

Targeted bispecific for treatment of inflammatory diseases

  • Improving therapeutic potential of bio-therapeutics by increasing drug concentrations to target tissues and limiting systemic exposure
  • A case study using a preclinical model of autoimmune arthritis will be presented
  • Use of customized protein database generated from RNA-Seq data to increase proteome coverage and validate novel isoforms for biomarker discovery
 
 
CMC and Developability
11:45

Reserved for KBI Biopharma

Protein Engineering
12:05

Biophysical characterization of bispecific antibodies for enhancement of dual-targeting specificity

  • Immunomodulatory mAb can employ multiple mechanisms in tumours
  • Potential mechanisms depend on mAb isotype and FcγR availability
  • mAb engineering can allow multiple mechanisms to be engaged to therapeutic effect
 
Armed Antibodies
12:05

Preclinical validation of site- specifically conjugated ADCs with potent anthracycline payloads in solid and hematologic tumor models

CMC and Developability
12:05

Establishing highly precise, low material consuming biophysical platform for biologics developability assessment

  • New biophysical applications for Biologics characterization using
    • Second Harmonic Generation (SHG)
    • Nano Digferential Scanning Fluorimetry (nano-DSF)
    • Microscale Thermophoresis (MST)
  • Kinetics for thermal stability and Activation energy barrier determination for Biologics stability assessment
  • Long-terms stability prediction by computational biophysical approaches

New formats and developability

 
 

Chaired by TBC

 
 
Protein Engineering
12:25

Creating multifunctional VH-based biologics using Humabodies from the Crescendo Mouse

  • Proprietary transgenic mouse generates highly diverse fully human VH domain (‘Humabody’) building blocks
  • Fully modular plug & play approach lacks the constraints of traditional mAbs and enables a radical rethink of how a multifunctional molecule can be designed and assembled to deliver enhanced therapeutic benefit.
  • Examples of differentiated biology will focus on applications in immuno-oncology and Humabody drug conjugates
 
 
Bispecifics
12:25

Application of the novel heterodimerization plattform Fc1k in mono- and multispecific molecules

  • Principles of the novel heterodimerization strategy
  • Generation of a lead candidate as platform module
  • Examples for bispecific applications
  • Future opportunities
 
Armed Antibodies
12:25

Functional disulfide re-bridging enables native full antibody DAR 2, 4 & 8 formation, site-selective orthogonal dual modification and homogeneous fragment drug conjugates

  • Site-selective modification of antibodies (including robust serum stability, in vitro selectivity, in vivo efficacy with options for DAR 2, 4 & 8, dual drug conjugates and fragment drug conjugates).
  • Use of chemical linkers to form bi- and tri-specific scaffolds 3. Application of technology to generate oriented antibody fragments on nanoparticle surfaces
 
CMC and Developability
12:25

Globally-optimised clinical candidates for maximised development success

  • Many therapeutic antibody candidates carry unnecessary amino-acid content in their binding domains
  • This extraneous content leads to significant proven CMC and clinical development risks
  • This presentation will present novel data translating fundamental antibody biology insights into improved-quality product candidates
 
Protein Engineering
12:45

Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics

  • Examined the role of IgG domains distal from the Fc in altering the affinity between IgG and FcRn
  • Identified that variable domains, and in particular complementarity-determining regions (CDRs), significantly alter binding affinity to FcRn in vitro and determined that affinity values correlated with calculated isoelectric point values
  • Demonstrated that tighter affinity values of IgG molecules to FcRn trend with faster in vivo clearance of a set of IgG molecules differing only by 1-3 mutations in human FcRn transgenic mice
 
Bispecifics
12:45

Early stage developability to enable bispecific design

Armed Antibodies
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
CMC and Developability
12:45

Clinical development of patient-centric injectable biologics-device combination products

  • The development of drug-device combination (DDC) products is a strategic imperative across the biopharmaceutical industry for injectable biologics 
  • A successful clinical strategy to address changes in manufacturing processes for drug substance as well as for DDC presentations needs to be risk-based and scientifically sound
  • An injectable DDC needs to be user-centric, and usability assessment in real-world clinical settings may be required to support the approval of a DDC
 

13:05 Networking Lunch

Protein engineering New formats and developability

Bispecific discovery

Armed antibody development – clinical development

Bioprocessing

Protein Engineering
14:35

Genetic encoding of a cyclopropene for the rapid and efficient generation of stable antibody conjugates

  • Efficient transient and stable expression systems
  • Rapid conjugation of tetrazine-bearing molecules
  • Dihydropyridazine bond stability in serum
  • Generation of a potent and selective ADC
 
Armed Antibodies
14:35

Reserved for Supporting Partner

if you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Protein Engineering
14:55

Antibody protein sequencing with mass spectrometry

  • Robust service to routinely sequence antibodies proteins directly
  • Accurate determination of Isoleucine and Leucine using mass spectrometry
  • Beyond 100% protein coverage by examine individual amino acid
Bispecifics
14:55

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Armed Antibodies
14:55

Title TBC

CMC and Developability
14:55

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Protein Engineering
15:15

Fighting pathogens and toxins with human and human-like antibodies

  • Recombinant antibodies for biodefense
  • Neutralizing and protective antibodies against viruses (Marburg virus, VEEV and WEEV)
  • Neutralizing and protective antibodies against toxins (botulinum toxins, diphtheria toxin)
  • Germline humanization of macaque antibodies
 
Bispecifics
15:15

CD47 targeting bispecific antibodies

  • Rationale for CD47 neutralization in cancer
  • Targeting CD47 with bispecific vs monoclonal antibodies – what’s the difference?
  • Blockade of CD47 with bispecific antibodies promotes tumour elimination in vivo and modifies the tumour microenvironment
 
Armed Antibodies
15:15

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Protein Engineering
15:35

Harnessing biotechnology against snakebite and other neglected tropical diseases

  • Snake venoms - a diverse arsenal of highly potent protein-based toxins
  • Cocktails of monoclonal human IgG antibodies with in vivo efficacy against snake venoms
  • Discovery of neurotoxin-targeting human IgGs using phage display technology
  • Using snake venom toxins to target parasitic diseases
 
Bispecifics
15:35

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Armed Antibodies
15:35

Improving single-cell delivery of antibody and protein-drug conjugates: Multiple strategies to increase drug distribution and efficacy

  • The distribution of cytotoxic payloads from antibody drug conjugates within a tumor, not just the total amount of payload, has a significant impact on efficacy
  • Multiple strategies can improve tumoral distribution including target selection, protein structure, and dosing to increase efficacy
  • These approaches and relevant examples will be discussed in the context of when each strategy is appropriate
 
CMC and Developability
15:35

The applications of charge based analytical methods in bioprocess development

  • cIEF method for purity analysis of mAbs
  • AEX method for analysis of tyrosine sulfation of a mAb
  • CEX method as process analytical technology tool (PAT)
 
 

15:55 Networking Break

Pharmacokinetics and the therapeutic window

Chaired by TBC

Dr Michael Streit
17:00

Increasing the therapeutic window and pharmacokinetics

Christoph Roesli
17:20

CMC strategies to influence pharmacokinetics

  • Mechanisms influencing the pharmacokinetics of antibodies
  • API-related critical quality attributes influencing pharmacokinetics
  • Considerations for antibodies with and without effector function
 
Frank Brennan
17:40

Safety testing of monoclonal antibodies: new targets, new molecules, new challenges

  • In silico review of target biology
  • Rationale mAb design/selection to avoid unwanted biological/immune effects
  • In vitro studies: pharmacology/immunosafety studies to characterise  Fab and Fc effects, off-target binding and immunogenicity 
  • In vivo studies: safety/efficacy/PD studies in normal/disease models
  • Using safety, PK/PD and M&S data to select safe human starting doses and escalation schemes
 
Kevin Bateman
18:00

Direct quantitation of therapeutic sntibodies for pharmacokinetic studies using immuno-purification and intact mass analysis

  • PK of mAbs has traditionally been measured using ligand binding assays
  • The use of mass spectrometry can complement LBA results
  • Results comparing LC-MS with LBA will be presented from GLP studies
 
18:20

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

18:40 Poster presentation and networking drinks reception

last published: 13/Jul/18 08:35 GMT

 

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates